Is Akari Therapeutics Plc – American Depositary Share (NASDAQ:AKTX) a Buy? The Stock Reported more Sellers

Akari Therapeutics, Plc (NASDAQ:AKTX) Logo

The stock of Akari Therapeutics Plc – American Depositary Share (NASDAQ:AKTX) registered an increase of 7.19% in short interest. AKTX’s total short interest was 234,200 shares in December as published by FINRA. Its up 7.19% from 218,500 shares, reported previously. With 20,200 shares average volume, it will take short sellers 12 days to cover their AKTX’s short positions. The short interest to Akari Therapeutics Plc – American Depositary Share’s float is 3.16%.

The stock increased 1.68% or $0.03 during the last trading session, reaching $1.82. About 5,267 shares traded. Akari Therapeutics, Plc (NASDAQ:AKTX) has declined 64.88% since December 11, 2017 and is downtrending. It has underperformed by 64.88% the S&P500.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company has market cap of $28.77 million. The Company’s lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. It currently has negative earnings. The firm is based in New York, New York.

More notable recent Akari Therapeutics, Plc (NASDAQ:AKTX) news were published by: which released: “Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2) – Seeking Alpha” on May 31, 2018, also with their article: “Penumbra (PEN) Forms JV on Virtual Reality in Health Space – Nasdaq” published on January 05, 2018, published: “Why I Purchased Stock In Celsus Therapeutics – Seeking Alpha” on June 01, 2015. More interesting news about Akari Therapeutics, Plc (NASDAQ:AKTX) were released by: and their article: “FDA accepts priority review of ALXN1210 as a treatment for patients with PNH in the US – Seeking Alpha” published on August 20, 2018 as well as‘s news article titled: “Akari Therapeutics Announces Appointment of David Horn Solomon as CEO – GlobeNewswire” with publication date: August 21, 2017.

Akari Therapeutics, Plc (NASDAQ:AKTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.